Title:
PHASE 2, multi-center, open-label investigation of HSPPC-96 vaccine with temozolomide in patients with newly diagnosed Glioblastoma Multiforme
Protocol Number:
J11107
Phase:
Phase II
Physician:
Michael Lim
Purpose:
Eligibility:
Patients over the age of 18 with newly diagnosed brain tumors concerning for a high grade astrocytoma /glioma are eligible for enrollment.
Treatment:
Population:
Adult
Last Update
05/18/2013 04:02 AM
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts